In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...
The LumiraDx NT-proBNP and the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test. Run on the highly portable LumiraDx Platform, they are ...
San Francisco, CA - Measurement of serum amino terminal fragment of prohormone brain-type natriuretic peptide (NT-proBNP) can add useful information to the standard risk assessment of people with ...
Jan. 6, 2006 — The US Food and Drug Administration (FDA) approved in 2005 a rapid point-of-care test for adenovirus in tear fluid as an aid in the differential diagnosis of acute conjunctivitis; a new ...
For recently diagnosed pulmonary arterial hypertension (PAH), adding sotatercept (Winrevair) to standard care lowered the ...
Blood test predicts cardiac events and death in heart patients By Steve Tokar Mary Whooley, MD A simple blood test for the protein NT-proBNP accurately predicts the risk of heart attack, heart failure ...
LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited, a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP ...
Zomedica launches two canine assays for TRUFORMA, including NT-proBNP for heart disease and progesterone for breeding. The assays provide reference lab-level accuracy in-clinic, enhancing diagnostics ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback